I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| retinal cone cell | 5 studies | 48% ± 24% | |
| hepatocyte | 4 studies | 63% ± 35% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| retinal cone cell | 5 studies | 48% ± 24% | |
| hepatocyte | 4 studies | 63% ± 35% |
Insufficient scRNA-seq data for expression of VTN at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 195439.04 | 226 / 226 | 100% | 4773.58 | 405 / 406 |
| adrenal gland | 100% | 9921.81 | 258 / 258 | 87% | 53.96 | 199 / 230 |
| pancreas | 100% | 624.67 | 327 / 328 | 82% | 51.10 | 146 / 178 |
| brain | 92% | 381.22 | 2424 / 2642 | 31% | 0.96 | 218 / 705 |
| bladder | 95% | 374.67 | 20 / 21 | 22% | 6.33 | 112 / 504 |
| kidney | 97% | 280.52 | 86 / 89 | 14% | 6.47 | 122 / 901 |
| ovary | 97% | 190.01 | 175 / 180 | 11% | 0.91 | 47 / 430 |
| uterus | 91% | 168.62 | 154 / 170 | 17% | 3.22 | 78 / 459 |
| lung | 85% | 136.34 | 489 / 578 | 16% | 9.82 | 183 / 1155 |
| heart | 98% | 1482.48 | 846 / 861 | 0% | 0 | 0 / 0 |
| prostate | 81% | 128.00 | 198 / 245 | 15% | 1.68 | 73 / 502 |
| blood vessel | 80% | 143.42 | 1070 / 1335 | 0% | 0 | 0 / 0 |
| stomach | 50% | 65.70 | 179 / 359 | 26% | 20.32 | 74 / 286 |
| spleen | 75% | 339.71 | 180 / 241 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 73% | 18.07 | 58 / 80 |
| esophagus | 50% | 66.35 | 722 / 1445 | 21% | 48.59 | 38 / 183 |
| breast | 55% | 74.81 | 253 / 459 | 12% | 2.89 | 134 / 1118 |
| adipose | 62% | 305.68 | 741 / 1204 | 0% | 0 | 0 / 0 |
| intestine | 44% | 52.23 | 423 / 966 | 15% | 11.20 | 81 / 527 |
| thymus | 49% | 53.91 | 323 / 653 | 5% | 0.50 | 32 / 605 |
| skin | 9% | 14.84 | 163 / 1809 | 24% | 2.26 | 114 / 472 |
| lymph node | 0% | 0 | 0 / 0 | 24% | 0.91 | 7 / 29 |
| peripheral blood | 14% | 58.48 | 127 / 929 | 0% | 0 | 0 / 0 |
| muscle | 3% | 3.21 | 25 / 803 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 2% | 0.06 | 1 / 45 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0061302 | Biological process | smooth muscle cell-matrix adhesion |
| GO_0033627 | Biological process | cell adhesion mediated by integrin |
| GO_0010951 | Biological process | negative regulation of endopeptidase activity |
| GO_0007160 | Biological process | cell-matrix adhesion |
| GO_0010811 | Biological process | positive regulation of cell-substrate adhesion |
| GO_0051918 | Biological process | negative regulation of fibrinolysis |
| GO_0032092 | Biological process | positive regulation of protein binding |
| GO_0035987 | Biological process | endodermal cell differentiation |
| GO_0030198 | Biological process | extracellular matrix organization |
| GO_0007155 | Biological process | cell adhesion |
| GO_0014911 | Biological process | positive regulation of smooth muscle cell migration |
| GO_0048260 | Biological process | positive regulation of receptor-mediated endocytosis |
| GO_0006955 | Biological process | immune response |
| GO_0016192 | Biological process | vesicle-mediated transport |
| GO_0051258 | Biological process | protein polymerization |
| GO_0097421 | Biological process | liver regeneration |
| GO_0050731 | Biological process | positive regulation of peptidyl-tyrosine phosphorylation |
| GO_0048709 | Biological process | oligodendrocyte differentiation |
| GO_0030195 | Biological process | negative regulation of blood coagulation |
| GO_0030949 | Biological process | positive regulation of vascular endothelial growth factor receptor signaling pathway |
| GO_0030155 | Biological process | regulation of cell adhesion |
| GO_0016477 | Biological process | cell migration |
| GO_0090303 | Biological process | positive regulation of wound healing |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005796 | Cellular component | Golgi lumen |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0062023 | Cellular component | collagen-containing extracellular matrix |
| GO_1904090 | Cellular component | peptidase inhibitor complex |
| GO_0072562 | Cellular component | blood microparticle |
| GO_0071062 | Cellular component | alphav-beta3 integrin-vitronectin complex |
| GO_0048237 | Cellular component | rough endoplasmic reticulum lumen |
| GO_0005783 | Cellular component | endoplasmic reticulum |
| GO_0098637 | Cellular component | protein complex involved in cell-matrix adhesion |
| GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
| GO_0005604 | Cellular component | basement membrane |
| GO_0008201 | Molecular function | heparin binding |
| GO_0030247 | Molecular function | polysaccharide binding |
| GO_0005201 | Molecular function | extracellular matrix structural constituent |
| GO_0042802 | Molecular function | identical protein binding |
| GO_0005178 | Molecular function | integrin binding |
| GO_0005044 | Molecular function | scavenger receptor activity |
| GO_0050840 | Molecular function | extracellular matrix binding |
| GO_0005518 | Molecular function | collagen binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | VTN |
| Protein name | Vitronectin (VN) (S-protein) (Serum-spreading factor) (V75) [Cleaved into: Vitronectin V65 subunit; Vitronectin V10 subunit; Somatomedin-B] Vitronectin |
| Synonyms | |
| Description | FUNCTION: Vitronectin is a cell adhesion and spreading factor found in serum and tissues. Vitronectin interact with glycosaminoglycans and proteoglycans. Is recognized by certain members of the integrin family and serves as a cell-to-substrate adhesion molecule. Inhibitor of the membrane-damaging effect of the terminal cytolytic complement pathway.; FUNCTION: Somatomedin-B is a growth hormone-dependent serum factor with protease-inhibiting activity. |
| Accessions | D9ZGG2 ENST00000542029.1 ENST00000226218.9 F5GX75 P04004 |
